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Objective: The effects of prolonged arteriovenous carbon dioxide removal on 
hemodynamics during severe respiratory failure were evaluated in adult 
sheep with severe smoke inhalation injury. Methods: Adult female sheep 
(n = 6, 33.8 --- 5.2 kg) were subjected to intratracheal cotton severe smoke 
insufflation to a mean carboxyhemoglobin level of 83% --. 3%. Twenty-four 
hours after injury, a low-resistance 2.5 m 2 membrane oxygenator was 
placed in a carotid-to-jugular pumpless arteriovenous shunt at unre- 
stricted flow to allow complete carbon dioxide removal and reductions in 
ventilator support. Animals remained conscious, and heart rate, cardiac 
output, mean arterial pressure, and pulmonary arterial pressure were 
measured at baseline, after injury, and daily during support with the 
arteriovenous carbon dioxide removal circuit for 7 days. Results: All animals 
survived the study period. Carbon dioxide removal ranged from 99.7 - 13.7 
to 152.2 - 16.2 ml/min, and five (83%) of the six animals were successfully 
weaned from the ventilator before day 7. During full support with the 
arteriovenous carbon dioxide removal circuit, shunt flow ranged from 
1.24 -+ 0.06 to 1.43 -- 0.08 L/min and accounted for 20.1% --. 1.4% to 25.9% 
_ 2.4% of cardiac output. No statistically significant changes in heart rate, 
cardiac output, mean arterial pressure, or pulmonary artery pressure were 
demonstrated over the study course despite the extracorporeal shunt flow. 
Conclusions: Arteriovenous carbon dioxide removal as a simplified means of 
extracorporeal gas exchange support is relatively safe without adverse 
hemodynamic effects or complications. (J Thorac Cardiovasc Surg 1997; 
114:1107-14) 
D espite advances in critical care, the adult respi- ratory distress syndrome (ARDS) still carries 
approximately a 50% mortality rate. 1'2 Current 
therapy is supportive as clinicians apply mechanical 
ventilation to assist oxygenation and promote car- 
bon dioxide (CO2) excretion. Mechanical ventilation 
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has well-recognized sequelae to both the injured 
and noninjured portions of the lung during the 
obligatory gas exchange. Sustained high airway pres- 
sures, with the use of either pressure- or volume- 
controlled modes of ventilation, lead to pressure- 
associated permeability edema 3 and histopathologic 
changes nearly indistinguishable from those seen in 
ARDS. 4 Recent work suggests alveolar overdisten- 
tion is mainly responsible for the damage. 5 To 
reduce the high pressures and associated barotrau- 
ma/volutrauma, recent ventilator management strat- 
egies limit inflation pressures at the expense of an 
increase in systemic CO 2 levels. This technique, 
termed permissive hypercapnia, has recently been 
shown to reduce the incidence of barotrauma/vo- 
lutrauma nd improve survival in ARDS. 6 
The success of venoarterial extracorporeal mem- 
brane oxygenation, 7 especially in the neonatal pop- 
ulation, has led to a resurgence in the use of 
extracorporeal techniques in the treatment of 
ARDS in the pediatric and adult populations. The 
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concept of venovenous extracorporeal CO 2 removal 
to allow a reduction in ventilatory support and 
associated barotrauma/volutrauma was applied by 
Gattinoni and associates 8' 9 to provide total CO 2 
extraction and satisfy systemic oxygenation require- 
ments using apneic oxygenation. 1° Both extracorpo- 
real CO2 removal and extracorporeal membrane 
oxygenation involve the use of an extracorporeal 
circuit and the attendant potential for related com- 
plications. 11 The intravenacaval oxygenator was de- 
veloped by Mortensen 12 to eliminate the need for 
extracorporeal blood circulation and still provide 
gas exchange. However, the intravenacaval oxygen- 
ator was limited by surface area and could only 
remove approximately 30% of the metabolic CO2 
production. 
To simplify the extracorporeal component and yet 
achieve adequate CO 2 removal, Barthelemy and 
colleagues 13 combined a pumpless artery-to-vein 
shunt with a membrane oxygenator and the ventila- 
tor management technique of apneic oxygenation to 
satisfy all the gas exchange needs of a large animal 
for up to 24 hours. Subsequently Awad and col- 
leagues 14 demonstrated the feasibility of prolonged 
extracorporeal CO2 removal (7 days) with the use of 
oxygenators designed for cardiopulmonary bypass 
interposed in an arteriovenous shunt in a healthy 
animal model without complications. Unfortunately, 
these studies were compromised by high circuit 
resistance (>30 mm Hg) to spontaneous arterio- 
venous blood flow, necessitating a mean arterial 
pressure greater than 110 mm Hg to achieve ade- 
quate flow for total CO2 removal. Other arterio- 
venous CO2 removal (AVCO2R) studies have also 
been accompanied by hemodynamic nstability. 15 
We recently developed an AVCOaR circuit with 
use of a new low-resistance membrane oxygenator 
to provide total CO 2 removal in both healthy a6 and 
injured 17 sheep models of severe respiratory failure. 
Total CO 2 removal could be achieved with signifi- 
cant reductions in minute ventilation and peak 
inspiratory pressures. In these studies, AVCO2R 
circuit flow was up to 1.4 to 1.6 L/min, representing 
approximately 20% to 29% of the animals' sponta- 
neous cardiac output with a circuit resistance less 
than 10 mm Hg. Although an arteriovenous shunt 
up to 29% cardiac output allowed a reduction in 
mechanical ventilatory support to approximately 
16% of the baseline requirements, the long-term 
impact on hemodynamic function during ARDS 
remains unknown. In the present study, we sub- 
jected adult sheep to a severe smoke inhalation 
injury to induce ARDS, then applied AVCO2R at 
sufficient shunt flow for total CO 2 removal to eval- 
uate the effect of sustained AVCO2R flow on critical 
hemodynamic variables over 7 days. This investiga- 
tion was necessary before our anticipated adult and 
pediatric linical AVCO2R trials for CO 2 retention 
syndromes and early ARDS. 
Material and methods 
All animals received humane care according to "Guide 
for the Care and Use of Laboratory Animals" (1985) 
prepared by the U.S. Department of Health and Human 
Services and published by the National Institutes of 
Health. The study was approved by the Institutional 
Animal Care and Use Committee of the University of 
Texas Medical Branch, Galveston, Tex., and performed 
with strict adherence to Committee guidelines regarding 
humane use of animals. 
Adult Suffolk ewes (n = 6, 33 + 5 kg) were used to 
investigate he effect of prolonged (7 days) AVCO2R in a 
smoke inhalation injury model of severe respiratory fail- 
ure. Femoral and pulmonary arterial lines were placed in 
the animals three days before the experiment. Baseline 
hemodynamic variables including heart rate, cardiac out- 
put, mean arterial pressure, pulmonary artery pressure, 
central venous pressure, and pulmonary artery wedge 
pressure were measured immediately before injury. After 
endotracheal intubation, anesthesia was maintained with 
inhaled halothane delivered through a volume-controlled 
ventilator (Servo 900C, Siemens-Elema). Tracheostomy 
was performed followed by cotton severe smoke inhala- 
tion/insufflation to induce severe respiratory failure to a 
median lethal dose as previously described, is Animals 
were then allowed to recover from anesthesia nd the 
lungs mechanically ventilated. Initial postinjury ventilator 
settings were as follows: respiratory rate 25 to 30 breaths/ 
min, tidal volume 15 ml/kg, fraction of inspired oxygen 
(Fio2) 1.0, and positive nd-expiratory pressure 5 cm H20. 
Fio 2 was reduced once the carboxyhemoglobin level was 
less than 10% and maintained at a level sufficient to 
provide an arterial oxygen tension (Pao2) level greater 
than 60 mm Hg. Hemodynamic variables and ventilator 
settings including minute ventilation and peak inspiratory 
pressure (PIP) were recorded. Arterial and mixed venous 
blood gas values were also measured every 6 hours, with 
minute ventilation and Fio 2 adjusted to maintain arterial 
pH at 7.35 to 7.45, Pao2 at 60 to 150 mm Hg, and arterial 
carbon dioxide tension (Paco2) at 30 to 40 mm Hg. 
After 24 hours of volume-controlled ventilation, the 
sheep were reanesthetized and underwent systemic anti- 
coagulation (300 IU/kg bovine lung heparin, Upjohn, 
Kalamazoo, Mich.) and cannulation of the left carotid 
artery (18F TF018LH, Research Medical, Midvale, Utah) 
and the left jugular vein (22F TF022L, Research Medi- 
cal). A membrane gas exchanger (Affinity, Avecor Car- 
diovascular, Plymouth, Minn.) was primed with normal 
saline solution (270 ml) and connected to the vascular 
cannulas after de-airing. Animals were then allowed to 
recover from anesthesia and have free access to food and 
water. Activated clotting time (Hemochron 400, Interna- 
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Fig. 1. CO 2 removal during 7 days Of AVCO2R in an ovine model of severe smoke inhalation injury peaks 
at day 5 and begins a slow downward trend as the animal recovers and resumes more efficient gas exchange 
via the native lungs. Values of Paco 2 (scaled on the right ordinate) remained within the normal range 
throughout the study. Values given as mean plus or minus the standard eviation. Baseline, Day 0, before 
injury; injury, day 0, before AVCO2R. 
tional Technidyne, Edison, N.J.) was maintained between 
300 and 500 sec with a continuous heparin infusion 
throughout the study. The animals were then allowed to 
recover and continued to receive ventilator support before 
initiation of AVCO2R. 
On the initiation of AVCO2R flow with extracorporeal 
CO2 removal, ventilator support was reduced in a stepwise 
fashion as previously described. 17 Initial reductions were 
made in tidal volume to reduce the PIP to less than 30 cm 
H20. Once targeted airway pressures were achieved, the 
respiratory rate was incrementally reduced to allow 
greater spontaneous respirations. Concurrently, the Fio 2 
was reduced as the Pao~ value remained above a threshold 
of 60 mm Hg. Positive end-expiratory pressure ranged 
from 5 to 10 cm H20. With full AVCO2R flow, ventilator 
reductions continued aily throughout the study period 
until repeated blood gas sampling demonstrated Pao 2 
values greater than 60 mm Hg with an Fio 2 of 0.21 and 
systemic Paco2 values remained less than 40 mm Hg, at 
which point mechanical ventilation was discontinued. 
Daily measurements of heart rate, cardiac output, mean 
arterial pressure, pulmonary artery pressure, blood flow, 
PIP, and CO 2 removal were recorded and systemic and 
pulmonary vascular esistance values were calculated and 
compared with baseline measurements. 
AVCO2R blood flow was monitored by an ultrasonic 
flow probe (model H6X, Transonic Systems, Ithaca, N.Y.) 
placed on the arterial cannula and interfaced with a 
real-time flowmeter (model HT 109, Transonic Systems) 
with a digital display. The arteriovenous pressure gradient 
across the gas exchanger was calculated on the basis of the 
difference between the inlet and outlet pressures. Sweep 
gas flow (100% oxygen) was controlled by an in-line 
regulator. CO 2 removal by the device was calculated as 
the product of sweep gas flow and its exhaust CO2 
concentration measured by an in-line capnometer (Sara- 
Trans, Lenexa, Kans.). The animals received 24-hour 
bedside care and continued to receive mechanical venti- 
lation for 7 days or until successfully weaned from venti- 
lator support. 
Data are expressed as mean plus or minus the standard 
error of the mean and were displayed and analyzed by the 
SigmaPlot and SigmaStat programs (Jandel Scientific, San 
Rafael, Calif.). Comparisons with baseline values (before 
injury) were made by one-way analysis of variance with 
Dunnett's test, with time treated as repeated measures. 
Results 
All animals survived the study period with five 
(83%) of six weaned from the ventilator before day 
7. AVCOzR allowed a reduction in ventilator pres- 
sure settings to maintain PIP at less than 30 cm H20 
throughout he study. CO 2 removal via AVCOzR 
ranged from 99:7 _+ 13.7 to 152.2 _+ 16.2 ml/min 
over the course of  the 7 days, while maintaining 
normocapnia (Paco2 -<40 mm Hg) (Fig. 1). Peak 
CO2 removal occurred at day 5 corresponding to the 
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Fig. 2. AVCO2R blood flow and cardiac output remained stable and AVCO2R flow ranged from 20.1% 
+ 1.4% to 25.9% _+ 2.4% cardiac output for 7 days. Values given as mean plus or minus the standard 
deviation. Baseline, Day 0, before injury; injury, day 0, before AVCO2R. 
anticipated full manifestation of the severe smoke 
inhalation injury. After day 5, as the animals' lungs 
recovered and native lung ventilation increased, 
AVCO2R blood flow was decreased in a stepwise 
fashion and extracorporeal CO2 removal subse- 
quently decreased. The values for extracorp0real 
flow rate, cardiac output, and flow as a percentage of
cardiac output can be seen in Fig. 2. AVCO2R flow 
throughout he 7-day study period ranged from 
1.24 + 0.06 to 1.43 + 0.08 L/min, accounting for 
20.1% + 1.4% to 25.9% _+ 2.4% of the cardiac 
output. Heart rate, mean arterial pressure, and 
pulmonary artery pressure values remained rela- 
tively constant and were not statistically different as 
compared with baseline values at any time during 
the study (Fig. 3). Likewise there were no significant 
changes in systemic or pulmonary vascular resis- 
tance associated with AVCO2R (Fig. 4). The pres- 
sure gradient across the oxygenator was less than 10 
mm Hg, and there were no changes in the inlet and 
outlet pressures throughout he 7-day study. No 
clots were observed in the AVCO2R circuit at 
necropsy. There were no observed incidences of 
acute or episodic hemodynamic nstability or hem- 
orrhagic or thromboembolic events throughout the 
7-day study. Despite the severity of the injury and 
significant reduction in ventilatory support, Pa% 
was maintained at greate r than 75 mm Hg with an 
Fio 2 of less than 0.5 at all times. 
Discussion 
Our recent work has shown that AVCO2R is a 
simple technique to achieve total CO 2 removal in a 
large animal model of ARDS in which flow up to 
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Fig. 3. Heart rate (HR), mean arterial pressure (MAP), and pulmonary artery pressure (PAP) during the 
7-day period of AVCO2R revealed no statistically significant differences at any time. Values given as mean 
plus or minus the standard eviation. Baseline, Day 0, before injury; injury, day 0, before AVCO2R. 
29% cardiac output achieved total CO 2 removal and 
significantly reduced minute ventilation and peak 
airway pressures. 17 In our initial studies of the 
performance characteristics of AVCO2R, we deter- 
mined that the quantity of CO 2 removed is directly 
dependent on blood flow through the gas exchang- 
er. i6 In healthy sheep, AVCO2R flow of 0.5 L/rain 
removes a sufficient quantity of CO 2 to maintain 
normocapnia, and mild permissive hypercapnia 
(Pac% of 60 to 70 mm Hg) results when AVCO2R 
flow is reduced to only 0.2 L/min. 19 Sufficient flow to 
achieve total CO z removal with AVCO2R allows a 
significant reduction in ventilator airway pressure 
requirements and attendant barotrauma/vo- 
lutrauma to the native lung alveoli. Before pediatric 
and adult clinical application of AVCO2R for CO 2 
retention syndromes or early ARDS, prolonged use 
of AVCO2R must be demonstrated to be tolerated 
hemodynamically without significant changes in heart 
rate, cardiac output, mean arterial pressure, pulmo- 
nary artery pressure, blood flow, PIP, or CO 2 removal. 
Therefore this study in a large animal model of ARDS 
was necessary to provide a risk/benefit assessment for 
the initial phase I clinical trials. 
Patients with ARDS are often in a hemodynami- 
cally unstable condition with a tendency toward 
either a hypodynamic z° or a hyperdynamic 21 state 
depending on the cause and progression of ARDS. 
Volume- or pressure-controlled mechanical ventila- 
tion inflicts positive intrapleural pressure and may 
exacerbate such instability by directly affecting ve- 
nous return and pulmonary vascular resistance. 
Modified ventilator management strategies, uch as 
varying levels of positive end-expiratory pressure 2z 
and manipulation of the inspiration/expiration ra-
tio, 23 have also been shown to change hemodynam- 
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Fig. 4. Systemic vascular esistance (SVR) and pulmonary vascular esistance (PVR) calculated from 
directly measured variables during the 7-day period Of AVCO2R revealed no statistically significant 
difference at any time. Values given as mean plus or minus the standard eviation. Baseline, Day 0, before 
injury; injury, day 0, before AVCO2R. 
ics or organ blood flow during ARDS in both animal 
models and human beings. Permissive hypercapnia 
leads to increases in cardiac output, organ blood 
flow, and intracerebral pressure, 24 but these effects 
can be attenuated by the administration of sodium 
bicarbonate to offset the respiratory acidosis. The 
overall disease proceSs and the resultant treatment 
are potentially additive in their impact on hemody- 
namic stability. The application of an additional 
treatment modality, that is, AVCO2R, which uses up 
to 20% to 30% of the cardiac output o alleviate the 
need for excessive ventilator therapy to remove 
CO2, could result in cardiac decompensation a d 
worsening of the condition. On the other hand, by 
allowing CO 2 removal to occur without he need for 
continued ventilation with potentially harmful evels 
of volume and pressure, AVCO2R allows a reduc- 
tion in the applied airway pressures and resultant 
intrathoracic pressures and minimizes the hemody- 
namic insult caused by impairment of venous return 
and cardiac output. These factors are paramount 
when considering AVCO2R for use and must be 
fully understood before a treatment is initiated that 
may predispose an already critically ill patient to 
further hemodynamic compromise. 
Early investigations into the physiologic response 
to an arteriovenous shunt in normal dogs showed 
that shunt flows ranging from 17% to 130% of the 
baseline cardiac output revealed either no change or 
a decrease of 10 to 30 mm Hg in mean arterial 
pressure. 2s Frank and coworkers 26 showed that a 
reflex vasoconstrictor response Prevented a fall in 
mean arterial pressure and that physiologic accom- 
modation occurred up to a shunt equal to or greater 
than 60% of the baseline cardiac output. These 
studies relied on extensive instrumentation in anes- 
thetized, healthy animals and may not accurately 
reflect the true adaptive response. A long-term 
(2-month) rat model of an aortocaval fistula, total- 
ing 50% of the cardiac output, demonstrated that 
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physiologic adaptation resulted in high-output car- 
diac failure with ventricular hypertrophy and re- 
gional blood flow redistribution. 27 This study illus- 
trated the adaptation to an unusually large shunt in 
the rat, but a more clinically relevant short-term 
study with significantly lower shunt flows is neces- 
sary for AVCO2R. 
Several examples of arteriovenous shunts used for 
specific patient care circumstances or large animal 
studies exist. Gentilello and colleagues 28-3° applied a 
simple percutaneous arteriovenous shunt connected 
to a countercurrent heat exchanger to speed re- 
warming in animals and patients with clinically 
significant hypothermia and reported aspontaneous 
arteriovenous shunt flow rate of 225 to 375 ml/min 
did not significantly alter hemodynamics. This 
method was significantly more efficient han simple 
external rewarming and was tolerated without ad- 
verse events or the need for anticoagulation. Awad 
and colleagues 14showed that AVCO2R support for 
up to 7 days could be tolerated without adverse 
hemodynamic sequelae in healthy dogs and sheep. 
More recently studies in a canine model of acute 
oleic acid injury with an oxygenator in a pumpless 
arteriovenous shunt with flow rates sufficient to 
achieve adequate gas exchange (25% of baseline 
cardiac output) resulted in decreases in mean arte- 
rial pressure and systemic vascular esistance that 
could be attenuated with a dopamine infusion. 15 
These studies were done in an anesthetized animal 
with an oleic acid model known to be associated 
with hemodynamic compromise. 31'32 
Our data confirmed that despite a 20% to 26% 
cardiac shunt through the AVCO2R circuit for 7 
days, there was no instability in the hemodynamic 
profile, specifically in heart rate, cardiac output, 
mean arterial pressure, pulmonary artery pressure, 
or AVCO2R flow. These data suggest that, in addi- 
tion to its use in healthy animals, 14'33 long-term, 
high-flow AVCO2R can be tolerated by adult sheep 
with severe respiratory failure without sequelae. The 
extremely low circuit resistance (<10 mm Hg) al- 
lows the AVCO2R circuit to appear as an insignifi- 
cant component of the overall systemic resistance 
without hemodynamic compromise on initiation of 
AVCO2R flow. Redistribution of blood flow, with 
decreased blood flow to muscles and skin and 
sustained blood flow to the brain and heart, has 
been observed in the high-shunt, high-output car- 
diac failure model in conscious rats. 27 Some ele- 
ments of this adaptive physiologic state may have 
been present during our 7-day study. In addition, 
increased intrathoracic pressure as a result of posi- 
tive-pressure ventilation will reduce venous return 
and subsequently cardiac output and systemic arte- 
rial blood pressure. By achieving a significant reduc- 
tion in ventilatory pressures and eliminating hyper- 
capnia, AVCO2R may have attenuated changes in 
hemodynamics that would have otherwise been 
manifested during the study as a result of increased 
intrathoracic pressure from mechanical ventilation. 
In our study, oxygenation was maintained with an 
Fio 2 ranging from 0.21 to 0.50, which was sufficient 
to maintain systemic Pao 2 values at greater than 75 
mm Hg throughout the 7 days. AVCO2R is not 
useful to provide supplemental 0 2 delivery when the 
arterial Pao2 level is adequate because the inflow to 
the gas exchanger is already well saturated, with 02 
carrying capacity at a maximum. To illustrate, he- 
moglobin is assumed to be 10 gm/dl, inlet 02 
saturation is 90% (corresponding to a Pao 2 value of 
60 mm Hg), outlet 02 saturation is 100%, and 
AVCO2R flow is 1.4 L/rain. The AVCO2R 0 2 
exchange capacity under these conditions is at a 
theoretic maximum of approximately 19 ml/min. 
Estimating 02 consumption at 150 to 250 ml/min 
per square meter, AVCO2R contributes little to the 
overall oxygenation i  a patient, especially in a 
patient who is in a hypermetabolic condition with an 
increased 02 demand related to the disease state. If 
the alveoli are maintained open with the application 
of positive end-expiratory pressure, the passive dif- 
fusion of constant-flow 02 across the alveolar mem- 
brane is adequate for systemic oxygenation asdem- 
onstrated by the technique of apneic oxygenation 
first popularized by Kolobow. 1° There is also a small 
benefit related to the increased O2 content of the 
mixed venous blood reaching the pulmonary precap- 
illary bed, which results in a slight alteration in the 
normal vasoconstrictive r sponse to local hypoxia 
with a resultant reduction in pulmonary shunt. 
In conclusion, AVCO2R can be used for total 
CO2 removal for up to 7 days in an adult sheep 
model of severe respiratory failure without hemody- 
namic compromise or instability. The blood flow 
rates necessary to achieve total CO2 removal by 
AVCOzR to provide lung rest may allow vascular 
access with percutaneous cannulas. Our goal is to 
provide a simple bedside management tool to aug- 
ment gas exchange in cases of developing ARDS to 
allow decreased barotrauma/volutrauma at an early 
stage when favorable outcomes are likely. In addi- 
tion, the relative hemodynamic stability of this ani- 
mal model of ARDS during prolonged AVCO2R 
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validates the safety of this technique for clinical 
trials to evaluate AVCO2R in syndromes of CO 2 
retention and early respiratory failure in the adult 
and, subsequently, pediatric populations. 
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